Skip to content

Rosa-Helena Bustos

3 papers in the library · 6 citations · publishing 2024-2025

Papers

Sort Most recent Most cited

Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic.

CNS Spectrums June 30, 2025 Jose-Manuel Quintero, Rosa-Helena Bustos, Sharon Lechtig-Wassermann et al. 6 citations

Ketamine, originally synthesized in 1962, has gained increasing attention due to its rapid and sustained antidepressant effects in treatment-resistant depression (TRD). Unlike traditional antidepressants, ketamine acts on multiple neurotransmitter systems, including NMDA receptor antagonism and AMPA receptor potentiation, offering a novel mechanism for mood regulation. Beyond psychiatry,...

Exploring psilocybin's role in mental health and palliative medicine: a path to improved well-being.

Expert Opinion on Emerging Drugs June 1, 2025 Maria-Alejandra Umbacia, Marta Ximena Leon, Jose-Manuel Quintero et al.

Although long known for their psychoactive effects, psychedelic drugs have only recently been investigated for medicinal use. Psilocybin has attracted the greatest interest with studies suggesting that it may be a useful agent in psychiatry and in palliative care. Clinical trials that included psilocybin were searched in PubMed, Embase, and ClinicalTrials.gov, demonstrating that adult...

Profiling the combination of bupropion and dextromethorphan as a treatment option for major depressive disorder.

Expert Review of Neurotherapeutics September 1, 2024 Joseph Blanco, Pamela Quimbaya, Manuel Mena et al.

Major Depressive Disorder (MDD) is a common mental health disorder marked by sadness, hopelessness, and anhedonia. Various therapies exist, but their effectiveness is limited. Dextromethorphan hydrobromide combined with bupropion hydrochloride (Auvelity®) is a recently approved alternative for treating this condition in adults. This review summarizes the neurobiology of major depression and...